Oct 22, 2019

ALZHEIMER'S DRUG


THE DRUG COMPANY BIOGEN SAYS IT WILL SEEK FEDERAL APPROVAL FOR A MEDICINE TO TREAT EARLY ALZHEIMER'S DISEASE, A LANDMARK STEP TOWARD FINDING A TREATMENT THAT CAN ALTER THE COURSE OF THE MOST COMMON FORM OF DEMENTIA. TODAY'S ANNOUNCEMENT IS A SURPRISE BECAUSE THE COMPANY EARLIER THIS YEAR STOPPED TWO STUDIES OF THE DRUG WHEN PARTIAL RESULTS SUGGESTED IT WAS NOT WORKING. THE COMPANY NOW SAYS A NEW ANALYSIS OF MORE RESULTS SUGGEST THAT AT THE HIGHEST DOSAGE THE DRUG HELPED REDUCE A DECLINE OF THINKING SKILLS. THE DRUG, CALLED ADUCANUMAB, AIMS TO HELP THE BODY CLEAR HARMFUL PLAQUES FROM THE BRAIN. SHARES OF MASSACHUSETTS-BASED BIOGEN SOARED 36% AFTER THE ANNOUNCEMENT.

Severe Weather Alert


Bookmark and Share